VTGN
VistagenยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
VTGN Profile
Vistagen Therapeutics, Inc.
A late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders
343 Allerton Avenue, South San Francisco, California 94080
--
Vistagen Therapeutics, Inc., founded on May 26, 1998, is a clinical-stage biopharmaceutical company dedicated to the development of a new generation of therapies for anxiety, depression and certain other central nervous system (CNS) diseases for which the current treatment options are insufficient, resulting in a large unmet need in a large and growing global market, The product line includes three clinical-stage CNS product candidates, PH94B, PH10 and AV-101, each with a different mechanism of action, superior safety in all clinical studies to date, and therapeutic potential in a variety of CNS indications.
